DCC-2618

Ref. 3D-FD103402

Informação sobre produto

• Nome: DCC-2618
• Marca: Biosynth
• Descrição: DCC-2618 is a zirconium oxide-based compound that binds to the ATP binding site of the Bcr-Abl kinase domain. The compound inhibits the phosphorylation of tyrosine residues in proteins on which it has been targeted, leading to cell death. DCC-2618 is an orally bioavailable drug that is well tolerated by patients. It is a potent inhibitor of myeloproliferative disorders and cancer cells with constitutive activation of the Bcr-Abl kinase domain. Inhibition of this kinase leads to cell cycle arrest, apoptosis, and suppression of tumor growth in mice.

Propriedades químicas

• Peso molecular: 489.47 g/mol
• Fórmula: C₂₆H₂₁F₂N₅O₃
• Pureza: Min. 95%